{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336691","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-08-06T11:05:06+00:00","discovered_at":"2026-08-06T11:10:07.335831+00:00","generated_at":"2026-08-06T11:10:21.623811+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Viridian reports Q2 net loss of $127M; Lumvoa FDA-approved and launched in June","bullets":["Lumvoa (veligrotug-vvze) approved by FDA for thyroid eye disease on June 26, 2026, and immediately launched in U.S.","Elegrobart BLA submission on track for Q1 2027; phase 3 trials showed robust proptosis reduction.","Cash, cash equivalents, and marketable securities of $981.5M as of June 30, 2026, up from $762.2M at March 31, 2026.","Net loss for Q2 2026 was $127.1M, compared to $100.7M in Q2 2025; R&D expenses decreased to $71.6M from $86.6M.","Completed convertible debt and equity financing in May 2026 with gross proceeds of $394M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336691","json":"https://secwatch.observer/filing/0001193125-26-336691.json","markdown":"https://secwatch.observer/filing/0001193125-26-336691.md","text":"https://secwatch.observer/filing/0001193125-26-336691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/0001193125-26-336691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:10:21.623811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}